Title
A case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes management.

Permalink
https://escholarship.org/uc/item/4fm0m6fz

Journal
Journal of the American Medical Informatics Association : JAMIA, 23(2)

ISSN
1067-5027

Authors
Neinstein, Aaron
Wong, Jenise
Look, Howard
et al

Publication Date
2016-03-01

DOI
10.1093/jamia/ocv104

Peer reviewed
A case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes management

Aaron Neinstein¹, Jenise Wong², Howard Look³, Brandon Arbiter³, Kent Quirk³, Steve McCanne³, Yao Sun⁴, Michael Blum¹, Saleh Adi²

ABSTRACT

Objective Develop a device-agnostic cloud platform to host diabetes device data and catalyze an ecosystem of software innovation for type 1 diabetes (T1D) management.

Materials and Methods An interdisciplinary team decided to establish a nonprofit company, Tidepool, and build open-source software.

Results Through a user-centered design process, the authors created a software platform, the Tidepool Platform, to upload and host T1D device data in an integrated, device-agnostic fashion, as well as an application (“app”), Blip, to visualize the data. Tidepool’s software utilizes the principles of modular components, modern web design including REST APIs and JavaScript, cloud computing, agile development methodology, and robust privacy and security.

Discussion By consolidating the currently scattered and siloed T1D device data ecosystem into one open platform, Tidepool can improve access to the data and enable new possibilities and efficiencies in T1D clinical care and research. The Tidepool Platform decouples diabetes apps from diabetes devices, allowing software developers to build innovative apps without requiring them to design a unique back-end (e.g., database and security) or unique ways of ingesting device data. It allows people with T1D to choose to use any preferred app regardless of which device(s) they use.

Conclusion The authors believe that the Tidepool Platform can solve two current problems in the T1D device landscape: 1) limited access to T1D device data and 2) poor interoperability of data from different devices. If proven effective, Tidepool’s open source, cloud model for health data interoperability is applicable to other healthcare use cases.

Keywords: diabetes mellitus type 1, insulin infusion systems, blood glucose self-monitoring, mobile applications, decision making, computer-assisted

BACKGROUND AND SIGNIFICANCE

Diabetes is one of the largest healthcare problems in the United States, with an estimated 29 million people having the disease (21 million diagnosed cases).¹ Each year, the United States sees 19 000 new cases of type 1 diabetes (T1D). T1D is the second most common chronic condition in children, trailing only asthma. T1D, which requires the replacement of insulin via subcutaneous injection, is unique among chronic diseases in its heavy reliance upon patient self-management. Patients make minute-to-minute decisions about their insulin dosing based on a multitude of factors such as current blood glucose (BG) level, food intake, and activity level. There is a very narrow margin for error, especially in children.² Taking either too much or too little insulin can cause dangerous and sometimes life-threatening high or low BG levels. To avoid this, insulin dosing regimens must be adjusted frequently and individually for each patient. Such personalized fine-tuning requires significant effort and is seldom done.³

The introduction of insulin pumps has made it possible to deliver insulin continuously and with great precision. Pumps more closely mimic physiological insulin secretion, giving variable “basal” rates throughout the day and delivering additional boluses for each meal or snack, or to bring down high BG levels.⁴ The use of continuous glucose monitoring (CGM) devices has allowed for tighter BG control⁵–⁷ which has been shown to reduce the rates of diabetes complications.⁸

Diabetes devices store a patient’s data, including insulin dose history, insulin pump settings, and BG values from BG meters and CGM devices. These data can be downloaded from devices into historical reports by patients or healthcare providers. Analyzing these reports can help a provider or patient identify BG trends and effects of insulin on BG levels. A patient’s insulin regimen can then be adjusted based on this analysis combined with a patient’s recall of her activities and life events. This individualized fine-tuning of insulin doses, known as “flexible intensive insulin therapy,” has been shown to improve quality of life and glycemic control in people with T1D.⁹ Despite this, only a small percentage of people with T1D use these historical reports to retrospectively review their device data and look for patterns to inform future dosing decisions.¹⁰–¹² Instead, most people with T1D use only their most recent BG reading to make insulin dosing decisions.¹³

Potential reasons for this lack of retrospective review of diabetes device data include the data silos and workflow challenges that exist with device downloading and data interpretation. Custom cables and proprietary software, often requiring different computer operating systems, are needed to download and view device data.¹⁴ Because
patients may use multiple devices from different vendors to manage their diabetes, it is often impossible for a patient to import all of her device data into one software application. Moreover, each software application has a unique user interface and data display paradigm, which would be akin to each EKG manufacturer developing their own data acquisition and display method rather than conforming to the standard.

Vendors have from time-to-time partnered with each other to directly pair their devices and create device-to-device interoperability—for example, an insulin pump from one vendor with a CGM from another vendor. Though these pairings consolidate real-time displays to improve the patient experience, they fail to address the underlying issue of proprietary data silos and their impact is thus limited. Numerous efforts have tried to facilitate an integrated download and data display from multiple vendors’ devices. SweetSpot, Diasend, and Glooko in that the standards will require implementation by device vendors. Despite so many efforts, the diabetes device data ecosystem remains fragmented and siloed.

Our strategy was to instead draw on the experience of the academic vertical silos of devices, data storage, and software.

Existing market dynamics make it difficult for the diabetes industry to address the problem of interoperability and instead encourage proprietary vertical silos of devices, data storage, and software. Our strategy was to instead draw on the experience of the communications industry, where companies providing proprietary and closed internet access like Prodigy, AOL, and Compuserve gave way to the open model of the World Wide Web. Just as cultivation of the Internet required non-profit funding, we felt the same would be true for an open data platform for diabetes management. We thus formed a non-profit corporation, Tidepool (tidepool.org), hypothesizing that a transparent process and organizational structure were critical to establish a new paradigm for management of diabetes device data.

Being nonprofit ensures that Tidepool in perpetuity prioritizes interoperability and open access over data silos and claims on market share. In this way, Tidepool aims to bolster the entire diabetes data ecosystem rather than competing over existing customers. If Tidepool is successful at catalyzing an open ecosystem with a large selection of diabetes apps, this may grow the overall device market, allowing all companies to sell more devices. The nonprofit, transparent structure facilitates a collaborative effort between our interdisciplinary team of academic endocrinologists, clinical informaticists, software developers, user interface experts, and technology entrepreneurs, most of whom either have T1D or family members with T1D. The nonprofit model has also helped Tidepool garner enthusiastic support from the T1D community at large, including patients, families, advocacy groups, and device makers.

A potential disadvantage of non-profit status is the inability to secure venture capital funding. Because venture capitalists have focused diabetes investments on the larger, more lucrative type 2 diabetes market rather than T1D, this concern is minimized for Tidepool. Tidepool’s startup funding has come from private philanthropists and granting agencies. Rather than relying on these sources indefinitely, Tidepool believes it can operate as a self-sustaining non-profit business, generating revenue through data hosting services. There are early indicators that this model can be successful.

In addition to choosing a non-profit status, our second major strategic decision was to create open-source software. We were inspired by the “open mHealth” model, believing that T1D is a particularly well-suited use case. The use of open-source software is consistent with our goals to reduce barriers to entry for new app developers, to foster collaboration, and to create software that is safe and secure. Identified factors favoring the use of open-source software in healthcare include: allowing universal access to the software, ensuring public scrutiny of the code, providing users the ability to add functionality and fix bugs without waiting for a company to do it, providing a toolkit that allows researchers to expand upon the software, and improving development efficiency. Because Tidepool will continually employ developers to maintain the software, code contributions from the open source community will augment rather than sustain the platform. Tidepool chose to use the Berkeley Software Distribution open-source license, a highly permissive license that allows third parties to leverage and repurpose any or all Tidepool code, maximizing the code’s potential impact. To date, nine employees and fifteen open source contributors have created code for Tidepool.

Tidepool’s development process is transparent beyond being open-source. All planning and technical documentation is openly published at GitHub. Third parties are free to use Tidepool’s code to run their own private installations, or they can apply for access to use Tidepool’s hosted data store for their own applications, a model used by many successful companies like WordPress. Tidepool’s nonprofit model and open ecosystem stand in contrast to the corporate philosophies and structures taken by SweetSpot, Diasend, and Glooko. Our hypothesis is that achieving broad impact on T1D device interoperability may require this unique combination of attributes.
The collaboration between academia and technologists has thus far proven critical, providing a broad set of resources. The University of California, San Francisco (UCSF) offered a healthcare-specific entrepreneurship course where we formulated potential business models.42 UCSF’s Center for Digital Health Innovation is working to integrate Tidepool with its electronic health record (EHR). Clinical researchers on our team reinforced the need to prioritize validation and evaluation of the Tidepool Platform and subsequent apps on meaningful patient-oriented and clinical outcomes, building the necessary structure into the product. Reciprocally, Tidepool’s technical and product design team have provided expertise not typically available in-house at academic institutions. Together, we aimed to surge forward with the agility of a startup company to create a modern, user-friendly system, while developing the meaningful medical content and clinical workflows necessary for a useful health tool.

RESULTS
The Tidepool Platform
The Tidepool Platform provides a hub for patients’ diabetes device data, along with open access for third-party apps to communicate with the platform using RESTful application program interfaces (APIs). The Tidepool Platform is device-agnostic, ingesting data from any vendor’s device(s) and then allowing any app to connect to the platform to use that data (Figure 1). This eliminates the current one-to-one relationship between T1D device hardware and software (Figure 2). As the foundation for future development of T1D apps, the Platform was built to handle “back-end” components such as security and authentication, data storage, and HIPAA compliance. Thus, software developers can focus on building engaging and useful apps without having to worry about developing a new back-end themselves. Of note, Tidepool’s software is still in an early stage of implementation, currently in use by a small group of beta testers and in a pilot study at the UCSF as well as by clinics associated with the ReplaceBG study coordinated by the Jaeb Center for Health Research.

Blip App
In parallel with development of the Platform, Tidepool created Blip, the first app built on the Platform. Blip combines an individual patient’s data from multiple devices into a single integrated display, allowing patients to look for relationships between carbohydrate intake, insulin boluses, and rising or falling glucose levels.

The Tidepool Platform: Engineering and Architecture Principles
In addition to being open-source, we consider 6 other engineering principles as core to the Tidepool Platform.

Small, Modular Pieces
Code built in small, modular pieces makes each element more manageable to design, build, and test, as well as allowing easy isolation in the case of a problem.43 In an open-source environment, having small pieces makes it easier for many developers to contribute code. The Tidepool Platform is currently composed of 16 different components in 5 groups (Table 1), working together to create the desired functions of the system (Figure 4).

Modern web design
Tidepool uses modern software architecture (see Table 2), including designing the software around RESTful principles,44 which the Agency for Healthcare Research and Quality (AHRQ) recently called the “foundation” of an interoperable healthcare system.45 In a RESTful system, major system components are both accessed by and communicate using standard (rather than proprietary) web protocols. This makes it easier to design and deploy the pieces individually and independently, which aids in robustness and ease of maintenance. It also reduces the complexity for client software, as there are mature tools in every programming language for communicating with RESTful APIs. This standard toolkit lowers the barriers to development.

Tidepool’s server systems use a set of interoperating RESTful protocols that are publicly accessible online.46 Tidepool’s apps use those protocols to communicate with the servers. A JavaScript library that encapsulates client communications with the Tidepool Platform is also freely available online.40

Cloud-computing
Tidepool’s “Platform as a Service” model relies on cloud-computing (Figure 5). The cloud model, with centralized data storage and online access to computing resources, allows access to data from any place, at any time, from any source.47–49 Cloud computing is still nascent in healthcare despite being standard in many other business applications. Schweitzer et al.50 noted that cloud-based healthcare software could be more efficient and less expensive than traditional enterprise software, could promote interoperability and data exchange, and
would be more responsive to changes. By relying on an intermediary vendor, cloud computing’s potential limitations include security and privacy risks as well as the risk of service interruption.

Client software products for the Platform are built as web applications using JavaScript and HTML. Storing and delivering software over the web means that users can always access the most recent software version, seamlessly benefiting from the latest advancements and bug fixes.

**Agile software development**

Tidepool uses agile software development methodology, which prioritizes the flexibility to adapt to changing product needs over adhering to a pre-specified project plan as is done in “waterfall” development models. Healthcare customer needs are complicated and often poorly understood at the outset. Agile methodology allows many stakeholders (i.e., clinicians, researchers, patients, caregivers, and IT departments) to shape software development over time.

Tidepool’s development cycles are limited to 2-week time periods. Any functionality estimated to require more development time is broken into sub-deliverables. This helps Tidepool try to quickly deliver functionality to end-users, often with multiple new software releases delivered in a 2-week period. These 2-week periods are referred to as “sprints.” The sprint methodology gives Tidepool a structure to maintain course when priorities remain constant or adapt quickly as priorities or user needs shift.

**User-centered design**

User-centered design involves iterative cycles during the design and development process that involve user input at every stage. While this approach can “maximize user motivation and engagement, reduce system failure or dramatic revisions, and provide greater feasibility and sustainability,” one review found that only 18% of mobile diabetes apps studied described a user-centered design process.

By contrast, user-centered design has been a core process in developing the Tidepool Platform and its initial app for data visualization, Blip. In its first 18 months, Tidepool has conducted 502 interviews with patients, clinicians, researchers, device makers, and software developers. With few exceptions, these meetings were conducted either face-to-face or via video conference, consistent with “Lean Startup” methodology. As Tidepool meets with users and perceives the need for new functionality, an application or sub-component of an application is coded into a functioning prototype. Over the course of several weeks, that prototype is shared with dozens of constituents. Feedback is collected in real time and additions are made daily, so often no two testers will experience the identical prototype.

Early prototype versions are also shared with patients and their families in a “beta” release. The beta is distributed via the web, along with assignments for the user to complete that provide structured feedback. Through April 2015, 49 patients and families had been
invited to participate in the beta, with 32 invitees participating and submitting feedback. Concurrent with this user-centered design process, we have been collecting user data and feedback on the Blip app as part of an IRB-approved pilot study at UCSF.

Security and privacy
The Platform uses a government-standard algorithm for encryption and data are encrypted both at rest and during transport. User data, such as log-on information, is stored and encrypted separately from patient data, which includes health and demographic data. All pieces of the system are located behind a firewall (Figure 4); only the router is accessible to the global Internet. An app server delivers client applications like Blip to individual computers, which then communicate to the Tidepool cloud to provide user services and medical data.

The Platform has undergone security assessments following the National Institute of Standards and Technology controls at 2 large healthcare systems. These include questions about: platform architecture, data management practices (policies for storage and access, encryption, and data breaches), restrictions on external access (firewalls, access keys, and security roles and permissions), and third-party vendors used (including business associate arrangements). Tidepool has implemented the Platform in a way that meets all federal Health Insurance Portability and Accountability Act (HIPAA) requirements and has signed business associate agreements with UCSF and with Amazon Web Services (required because Tidepool uses Amazon’s cloud servers).

DISCUSSION
The Tidepool Platform offers many opportunities to improve technologies that enable clinical care and research for T1D (summarized in Table 3 and described below).

Potential Advantages for Diabetes App Development
Apps built on the Tidepool Platform can offer unique front-end functionality while sharing a common data structure and back-end (Figure 6). This open access to a shared back-end lowers the barrier to entry for developers with creative ideas for new diabetes apps. Apps can easily be interoperable with other apps and developers will have broader access to data and other functionalities than they would have if they built a standalone app. Interoperability of health technology can potentially improve patient safety, protect against lost and missing data, and improve efficiency of care.

Other industries have similarly benefited from a move from closed and proprietary ecosystems to open, standards-based, multi-vendor ecosystems. This “co-opetition” provides greater flexibility due to more potential device permutations, lower costs, and movement by companies toward higher value activities.
Potential Benefits to Clinical Care

The Tidepool Platform will allow people with diabetes to identify and use apps that uniquely address their individual needs, choosing apps based on functionality rather than based on whichever input device(s) they are using. Promoting connections between apps enables the inclusion of data sources, such as food and activity tracking apps or heart rate sensors, which are not typically used alongside BG or insulin data. Putting these data alongside more traditional diabetes device data improves context, facilitating the review of life events that coincide with a diabetes-related event such as a hypoglycemic episode. Prior evidence has shown that integrating contextual data is helpful in T1D management.

Cloud-based apps built for the Tidepool Platform, like Blip, can facilitate the sharing of diabetes device data and ongoing communication between patient and provider. This communication is often lacking, creating a barrier to improved glycemic control. More frequent clinician review of patient-generated diabetes data along with feedback to the patient has been shown to improve hemoglobin A1c. Developing rapid feedback loops between a patient and provider could facilitate “teachable moments,” whereby providers could guide patients toward learning how specific life events impact glycemic control. Integration of diabetes device data with EHRs could facilitate these rapid feedback loops by placing diabetes device data into healthcare provider workflows. Having a single open-source platform like Tidepool could facilitate EHR integration since health IT departments would only need to integrate one back-end data source as opposed to creating a unique custom integration for each vendor device and application.

As development of closed-loop “artificial pancreas” systems progresses, there is a need for safety and monitoring software. The Tidepool Platform can fill this need, providing cloud-based data hosting, visualization, and analytic tools that would allow patients, providers, or regulatory agencies to track data from the artificial pancreas.

Potential Benefits to Diabetes Research

A cloud-based platform provides researchers with opportunities that were previously difficult to attain or unavailable with installed client software. Cloud-based storage allows data to be stored once but accessed by any number of authorized users. Thus, for example, Tidepool might give patients the ability to contribute their data to an anonymized research database. Any researcher would then be able to access this comprehensive dataset of openly available, high-quality, contextualized

---

### Table 3: Potential clinical and research advantages of an open diabetes platform.

| Current State | Open Platform |
|---------------|---------------|
| Near one-to-one relationship between device and application | Any application can use data from any device |
| Mobile apps require manual data entry by the user, leading to user burden and transcription errors | Mobile apps automatically access and collect device data |
| A provider must learn to interpret data presented in each unique software application and visualization format from each device vendor (or choose only one device to prescribe to their patients) | A provider selects and gains expertise using one software application of choice while still allowing patients the freedom to choose to use whichever devices they prefer |
| Patients may use devices (e.g., one pump and one continuous glucose monitoring device) from different vendors but are forced to sacrifice data interoperability | Patients who choose any permutation of devices are able to use device data in an integrated fashion |
| Mobile app developers must each develop a unique vertical product stack including back-end features (e.g., secure and private data storage) | App developers can focus on developing front-end, user-facing apps that integrate with the back-end of the Tidepool Platform |
| Diabetes software only uses and shows data from diabetes specific hardware | Diabetes software can incorporate data from any source, including trackers for fitness/activity, heart rate, and food |
| Device companies must devote resources to software development | Device companies can focus efforts and resources on hardware, their area of expertise |
| Clinical research studies utilizing devices are restricted in the permutations of devices they can use | Clinical research studies can use any combination of devices |
| Developing new clinical decision algorithms in research studies requires many slow iterations of testing, refinement, and then pushing out the updated algorithm for testing again | Researchers can more efficiently study clinical algorithms, pushing the algorithms out to users through the cloud and rapidly getting feedback about efficacy |
| Researchers must manually collect data for each new retrospective study they conduct | Researchers can access and query a comprehensive clinical data-set that is already collected |
diabetes device data, allowing novel research questions to be answered. Such a research database could be used to help simulate and test artificial pancreas algorithms before they are applied in patients.

Using the Tidepool Platform for data collection and hosting would relieve clinical researchers of the need to independently set up a data collection system for each research study, improving efficiency and decreasing research costs. This infrastructure is already being used to support a multi-center clinical study involving 275 patients.

Clinical researchers will have new opportunities to evaluate the efficacy of T1D software. The current one-to-one bond between device and software has created few opportunities to compare the efficacy of T1D software independent of the devices collecting the data. In studies showing improved quality of life and clinical outcomes for users of insulin pumps and CGM devices, device-software combinations have been analyzed rather than individual components. Only 2 published studies have compared patients on insulin pumps who used the vendor-provided software to those on insulin pumps who did not use the software.

Researchers could use the Tidepool Platform and cloud analytics tools to evaluate user engagement with and efficacy of specific components or combinations of components of diabetes apps. These more precise insights are currently lacking in most published diabetes mobile app studies, which tend to follow the “black box” model of evaluation. Usability testing methods not typically seen in healthcare might be possible, such as “A/B testing,” where researchers can perform repeated usability tests of small variations in their apps with a high frequency of iterations.

CONCLUSION
Both the Tidepool Platform and its development process, if proven to be effective, can serve as models for future healthcare technology innovation. The Tidepool Platform’s open software code is adaptable for use beyond T1D in other chronic diseases that rely on patient-generated multi-sourced data, such as type 2 diabetes, asthma, or congestive heart failure.

Tidepool’s success would illustrate that an “open mHealth” model can facilitate interoperability and would suggest that proprietary vendor data silos are a restrictive and outdated model. Tidepool, though still in its early stages, has already catalyzed a vibrant dialogue and meaningful contributions from T1D advocacy groups, healthcare providers, researchers, software developers, and device manufacturers worldwide. Tidepool has stimulated a virtuous cycle in the T1D device ecosystem, as a majority of diabetes device manufacturers have committed to opening their data protocols to Tidepool. The future implementation of data protocol standards will create more efficiency in this open innovation ecosystem, obviating Tidepool of the need to implement device protocols one at a time.

We hope that apps built on the Tidepool Platform—like Blip—can facilitate better self-management and clinical diabetes outcomes through improved data accessibility and improved feedback and communication between patient and provider. We foresee that the Tidepool Platform will spur the development of many useful new apps for T1D beyond Blip, meeting patient and provider needs in ways that were not previously possible when data was trapped in silos.

COMPETING INTERESTS
S.A. owns publicly traded shares in Dexcom and Tandem, and serves as member of the Scientific Advisory Board for Tandem. H.L. and B.A. are paid employees of Tidepool, a nonprofit corporation. H.L. owns publicly traded shares in Dexcom.

FUNDING
Tidepool has been funded by grants from the JDRF, the Goldsmith Foundation, The Helmsley Charitable Trust, and by private philanthropy. J.W. receives research support from an NIH K12 award, DK094726. A.N. has received research support from an NIH T32 grant.
ACKNOWLEDGEMENTS

We would like to acknowledge the Tidepool employees and members of the public who have donated their time, energy, and software code toward the Tidepool Platform. We would also like to acknowledge the many device companies, healthcare providers, researchers, patients, and families who have contributed to this effort.

REFERENCES

1. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Centers for Disease Control and Prevention; 2014 GA, Atlanta.
2. Adi S. Type 1 diabetes mellitus in adolescents. Adolesc Med State Art Rev. 2010;21(1):86–102.
3. Walsh JP, Wroblewski D, Bailey TS. Insulin pump settings: a major source for insulin dose errors. Diabetes Technology Meeting [October 25, 2007]. http://www.diabetesnet.com/pdfs/DiaTech2007Poster.pdf
4. Meade LT, Rushton WE. Optimizing insulin pump therapy a quality improvement project. Diabetes Educ. 2013;39(6):841–847.
5. Klonoff DC, Blonde L, Cembrowski G, et al. Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes. J Diabetes Sci Technol. 2011;5(6):1529–1548.
6. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–774.
7. Yeh H-C, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(9):336–347.
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
9. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746–749.
10. Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2011;97(12):4383–4389.
11. Corriveaux EA, Durso PJ, Kaufman ED, Skipper BJ, Laskaratos LA, Heintzman KB. Effect of Carelink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(4p2):360–366.
12. Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014;37(10):2702–2709.
13. Lawton J, Rankin D, Cooke D, et al. Patients’ experiences of adjusting insulin doses when implementing flexible intensive insulin therapy: a longitudinal, qualitative investigation. Diabetes Res Clin Pract. 2012;98(2):236–242.
14. Picton PE, Yeung M, Hamming N, Desborough L, Dassau E, Caffazzo JA. Advancement of the Artificial Pancreas through the Development of Interoperability Standards. J Diabetes Sci Technol. 2013;7(4):1066–1070.
15. FDA Approval for Animas Vibe Insulin Pump with Dexcom G4 PLATINUM CGM. 2014 [cited April 15, 2015]. http://www.medgadget.com/2014/12/fda-approval-for-animas-vibe-insulin-pump-with-dexcom-g4-platinum-cgm-video.html
16. MedGadget Editors. FDA Approval for Animas Vibe Insulin Pump with Dexcom G4 PLATINUM CGM. In: MedGadget, ed. 2014.
17. Tandem Diabetes Care and Dexcom Expand Development and Commercialization Agreement to Include Recently Approved G4™ PLATINUM CGM Sensor. In: NewswireP, ed. 2013.
18. Diasend. [cited March 5, 2015]. http://www.diasend.com/us/
19. Glooko. [cited March 5, 2015]. http://www.glooko.com
20. Sweetspot Diabetes Care. [cited March 5, 2015]. http://www.sweetspotdia betes.com.
21. DexCom, Inc. Announces Acquisition of SweetSpot Diabetes Care, Inc. 2012 [cited April 15, 2015]. http://www.businesswire.com/news/home/201202 3006633/en/DexCom-Announces-Acquisition-SweetSpot-Diabetes-Care- V56EcptF_rl.
22. Rao L. Glooko Raises $3.5M To Connect Glucose Meters To iPhones For Tracking Diabetes. 2012 [cited April 15, 2015]. http://techcrunch.com/ 2012/01/30/glooko-raises--3-5m-to-connect-glucose-meters-to-iphones-for-tracking-diabetes/.
23. Baum S. Glooko adds Medtronic as investor in $16.5M Series B. In: News M, ed. 2015.
24. Bergenstall RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Therapeutics. 2013;15(3):198–211.
25. IEEE. Health informatics—Personal health device communication - Part 20601: Application profile—Optimized Exchange Protocol. IEEE.
26. IEEE. Health informatics—Personal health device communication - Part 10425: Device Specialization—Continuous Glucose Monitor (CGM); standard-sieeorg, in press.
27. Demidowich AP, Lu K, Tamler R, Bloomgarden Z. An evaluation of diabetes self-management applications for Android smartphones. J Telemed Telecare. 2012;18(4):235–238.
28. El-Gayar O, Timsina P, Nawar N, Eid W. A systematic review of IT for diabetes self-management: are we there yet? Int J Med Inform. 2013;82(8):637–652.
29. Eng DS, Lee JM. The promise and peril of mobile health applications for diabetes and endocrinology. Pediatric Diabetes. 2013;14(4):231–238.
30. Mulvaney SA, Ritterband LM, Bosslet L. Mobile intervention design in diabetes: review and recommendations. Curr Diab Rep. 2011;11(6):486–493.
31. Dyer JS. Effects of consumer-facing technologies on patient engagement, behavior change, and type 2 diabetes–related health outcomes. Diabetes Spectrum. 2014;26(2):98–101.
32. The PLOS Medicine Editors. A reality checkpoint for mobile health: three challenges to overcome. PLoS Med. 2013;10(2):e1001395.
33. Tomlinson M, Rotheram-Borus MJ, Swartz L, Tsai AC. Scaling Up mHealth: where is the evidence? PLoS Med. 2013;10(2):e1001382.
34. Gagne K, Lake M. CompSure, Prodigy et al: what Web 2.0 can learn from Online 1.0. Computerworldcom July 15, 2009 [cited February 3, 2015]. http://www.computerworld.com/article/2526547/networking/compsure–prodigy-et-al—what-web-2-0-can-learn-from-online-1-0.html
35. Leiner B, Cerf V, Clark D, et al. Brief History of the Internet. internetsoci ety.org [cited]. http://www.internetsociety.org/internet/what-internet/history internet/brief-history-internet.
36. Tidepool. [cited]. http://tidepool.org/
37. Estrin D, Sim I. Health care delivery. Open mHealth architecture: an engine for health care innovation. Science. 2010;330(6005):759–760.
38. Gentleman RC, Carey VJ, Bates DM, et al. Biocomputer: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
39. Look H. Tidepool License Update. December 19, 2013 [cited March 6, 2015]. http://tidepool.org/2013/12/19/tidepool-license-update/
40. Github- Tidepool. [cited March 6, 2015]. https://github.com/tidepool-org/ platform-client
41. Wordpress. [cited March 5, 2015]. http://www.wordpress.com
42. Blank S. Lean Launchpad for Life Sciences and Healthcare. San Francisco, CA. 2013. September to December 2013.
43. Weinberger D. Small Pieces, Loosely Joined. 1 edn. Basic Books: New York, NY. 2003.
44. Fielding RT, Taylor RN. Principled design of the modern Web architecture. ACM Transact Internet Technol (TOIT). 2002;2(2):115–150.
45. Data for Individual Health: Agency for Healthcare Research and Quality. 2014. JASON. (a committee/group), Agency for Healthcare Research and Quality, McLean, VA.
46. Tidepool Developer Portal. [cited March 6, 2015]. http://developer.tidepool io
47. Lawton G. Developing software online with platform-as-a-service technology. Computer. 2008;41(6):13–15.
48. Rolim CO, Koch FL, Westphall CB, Werner J, Fracalossi A, Salvador GS. A cloud computing solution for patient’s data collection in health care institutions. Second International Conference on eHealth, Telemedicine, and Social Medicine. IEEE; 2010: 95–99.

49. Armbrust M, Fox A, Griffith R, et al. A view of cloud computing. Commun ACM. 2010;53(4):50–58.

50. Schwarzer EJ. Reconciliation of the cloud computing model with US federal electronic health record regulations. JAMIA. 2011;19(2):161–165.

51. Highsmith J, Cockburn A. Agile software development: the business of innovation. Computer. 2001;34(9):120–127.

52. McConnell S. Chapter 7: Lifecycle Planning. O’Reilly

53. van Mierlo T, Fournier R, Jean-Charles A, Hovington J, Ethier I, Selby P. I’ll Txt U

54. Wyatt JC, Liu JLY. Basic concepts in medical informatics. J Epidemiol Commun Health. 2002;56(1):808–812.

55. Schwaber K. Scrum development process.

56. McCurdie T, Taneva S, Casselman M, et al. mHealth consumer apps: the case for user-centered design. Biomed Instrum Technol. 2012;(Suppl):49–56.

57. Blank S. Building a Company with Customer Data — Why Metrics Are Not Enough. 2009 [cited April 21, 2015]. http://steveblank.com/2009/12/17/building-a-company-with-customer-data-metrics-are-not-enough/

58. Announcing the Advanced Encryption Standard (AES). csrcnistgov: Federal Information Processing Standards Publication No. 197; 2001.

59. Security and Privacy Controls for Federal Information Systems and Organizations. NIST Special Publication: National Institute of Standards and Technology; 2013. Gaithersburg, MD.

60. Association for the Advancement of Medical Instrumentation. Medical Device Interoperability. A Safer Path Forward: AAMI-FDA Interoperability Summit; Herndon, VA. 2012:52.

61. Bengtsson M, Kock S. “Coopetition” in business networks—to cooperate and compete simultaneously. Ind Market Manage. 2000;29(5): 411–426.

62. Rossi MCE, Niccolucci A, Di Bartolo P, et al. Diabetes interactive diary: a new telemmedicine system enabling flexible diet and insulin therapy while improving quality of life: an open-label, international, multicenter, randomized study. Diabet Care. 2010;33(1):109–115.

63. Liang X, Wang Q, Yang X, et al. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med. 2011;28(4):455–463.

64. Lawson PJ, Flocke SA. Teachable moments for health behavior change: a concept analysis. Patient Educ Couns. 2009;76(1):25–30.

65. Phillip M, Battelino T, Atlas E, et al. Outpatient glycemic control with an artifical pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824–833.

66. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371(4):313–325.

67. Williams AJ, Wilbanks J, Ekins S. Why open drug discovery needs four simple rules for licensing data and models. PLoS Comput Biol. 2012;8(9): e1002706.

68. A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes. T1D Exchange Clinic Network Coordinating Center: Boston, MA, 2014.

69. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med. 2007;24(6):607–617.

70. Mauras N, Fox L, Englert K, Beck RW. Continuous glucose monitoring in type 1 diabetes. Endocrine. 2013;43(1):41–50.

71. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103.

72. Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabet Care. 2007;30(6):1653–1662.

73. Phillip M, Danne T, Shalitin S, et al. Use of continuous glucose monitoring in children and adolescents. Pediatric Diabetes. 2012;13(3):215–228.

74. Shalitin S, Ben-Ari T, Yakobovitch-Gavan M, et al. Using the Internet-based upload blood glucose monitoring and therapy management system in patients with type 1 diabetes. Acta Diabetol. 2013;51(2):247–256.

75. Baker TB, Gustafson DH, Shah D. How can research keep up with eHealth? Ten strategies for increasing the timeliness and usefulness of eHealth research. J Med Internet Res. 2014;16(2):e36.

76. Chopra P. The Ultimate Guide to A/B Testing. 2010 [cited May 29, 2014]. http://www.smashingmagazine.com/2010/06/24/the-ultimate-guide-to-a-b-testing/

AUTHOR AFFILIATIONS

1Department of Medicine and Center for Digital Health Innovation, University of California, San Francisco, CA, USA

2Department of Pediatrics and Madison Clinic for Pediatric Diabetes, University of California, San Francisco, CA, USA

3Tidepool, Palo Alto, CA, USA

4Department of Pediatrics, University of California, San Francisco, CA, USA